Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (39)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sheean, G. L.
Right arrow Articles by Thompson, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sheean, G. L.
Right arrow Articles by Thompson, A. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol 121, Issue 5 967-975, Copyright © 1998 by Oxford University Press

ARTICLES

An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis

GL Sheean, NM Murray, JC Rothwell, DH Miller and AJ Thompson
Department of Clinical Neurophysiology, National Hospital for Neurology and Neurosurgery, London, UK.

We studied the electrophysiological parameters of motor performance in eight patients with multiple sclerosis and troublesome fatigue, before and after treatment with 3,4-diaminopyridine. Symptomatic fatigue was evaluated by the Krupp Fatigue Severity Score and motor performance of adductor pollicis by transcranial magnetic stimulation, rapid voluntary movements and a fatiguing exercise test of a sustained 45-s isometric contraction. The motor tests revealed baseline abnormal motor function and substantial central fatigue. After a 3-week course of 3,4- diaminopyridine (25-60 mg/day), six out of the eight patients reported substantial improvement in fatigue and the group showed slightly less fatigue on the exercise test. Other electrophysiological tests of motor function were unchanged. The findings suggest that 3,4-diaminopyridine may play a role in the symptomatic treatment of fatigue in multiple sclerosis. However, the mechanism behind such a benefit in fatigue remains unclear and the discrepancy between subjective and more objective responses underlines the probable multifactorial nature of the pathogenesis of this symptom in multiple sclerosis.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mult SclerHome page
P. Flachenecker and H. Meissner
Fatigue in multiple sclerosis presenting as acute relapse: subjective and objective assessment
Multiple Sclerosis, March 1, 2008; 14(2): 274 - 277.
[Abstract] [PDF]

Home page
 J. Appl. Physiol.Home page
M. L. Schillings, D. F. Stegeman, and M. J. Zwarts
Determining central activation failure and peripheral fatigue in the course of sustained maximal voluntary contractions: a model-based approach
J Appl Physiol, June 1, 2005; 98(6): 2292 - 2297.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
B. Stankoff, E. Waubant, C. Confavreux, G. Edan, M. Debouverie, L. Rumbach, T. Moreau, J. Pelletier, C. Lubetzki, M. Clanet, et al.
Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study
Neurology, April 12, 2005; 64(7): 1139 - 1143.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
H. Crayton, R. A. Heyman, and H. S. Rossman
A multimodal approach to managing the symptoms of multiple sclerosis
Neurology, December 14, 2004; 63(11_suppl_5): S12 - S18.
[Abstract] [Full Text]

Home page
 NeurologyHome page
C. Mainero, M. Inghilleri, P. Pantano, A. Conte, D. Lenzi, V. Frasca, L. Bozzao, and C. Pozzilli
Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine
Neurology, June 8, 2004; 62(11): 2044 - 2050.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
L. B. Krupp, L. G. Hyman, R. Grimson, P. K. Coyle, P. Melville, S. Ahnn, R. Dattwyler, and B. Chandler
Study and treatment of post Lyme disease (STOP-LD): A randomized double masked clinical trial
Neurology, June 24, 2003; 60(12): 1923 - 1930.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
E.-L. Glader, B. Stegmayr, and K. Asplund
Poststroke Fatigue: A 2-Year Follow-Up Study of Stroke Patients in Sweden
Stroke, May 1, 2002; 33(5): 1327 - 1333.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
P M Rossini, P Pasqualetti, C Pozzilli, M G Grasso, E Millefiorini, A Graceffa, G A Carlesimo, G Zibellini, and C Caltagirone
Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine
Multiple Sclerosis, December 1, 2001; 7(6): 354 - 358.
[Abstract] [PDF]

Home page
 Mult SclerHome page
S Merkelbach, U Dillmann, C Kolmel, J Holz, and M Muller
Cardiovascular autonomic dysregulation and fatigue in multiple sclerosis
Multiple Sclerosis, October 1, 2001; 7(5): 320 - 326.
[Abstract] [PDF]

Home page
 NeurologyHome page
G. Giovannoni, A. J. Thompson, D. H. Miller, and E. J. Thompson
Fatigue is not associated with raised inflammatory markers in multiple sclerosis
Neurology, August 28, 2001; 57(4): 676 - 681.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
L. B. Krupp and L. E. Elkins
Fatigue and declines in cognitive functioning in multiple sclerosis
Neurology, October 10, 2000; 55(7): 934 - 939.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.